• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.

作者信息

Arakaki Hideki, Nakazato Tomonori, Osada Yuki, Ito Chisako, Aisa Yoshinobu, Mori Takehiko

机构信息

Department of Hematology, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-8555, Japan.

Division of Hematology, Keio University School of Medicine, Tokyo, Japan.

出版信息

Ann Hematol. 2017 Jul;96(7):1225-1226. doi: 10.1007/s00277-017-3017-7. Epub 2017 May 15.

DOI:10.1007/s00277-017-3017-7
PMID:28508175
Abstract
摘要

相似文献

1
Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.利妥昔单抗联合环磷酰胺、长春新碱和泼尼松（R-CVP）与利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）用于80岁及以上弥漫性大B细胞淋巴瘤老年患者的比较。
Ann Hematol. 2017 Jul;96(7):1225-1226. doi: 10.1007/s00277-017-3017-7. Epub 2017 May 15.
2
Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.老年非霍奇金淋巴瘤患者的减量（三分之二剂量）R-CHOP化疗
J Chemother. 2015 Feb;27(2):99-105. doi: 10.1179/1973947814Y.0000000219. Epub 2014 Oct 14.
3
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.伊布替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗初治 CD20 阳性 B 细胞非霍奇金淋巴瘤患者：一项非随机、1b 期研究。
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
4
Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.利妥昔单抗-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者的中性粒细胞减少模式及发热性中性粒细胞减少的危险因素
J Korean Med Sci. 2014 Nov;29(11):1493-500. doi: 10.3346/jkms.2014.29.11.1493. Epub 2014 Nov 4.
5
Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.在利妥昔单抗时代，弥漫性大 B 细胞淋巴瘤患者的监测 FDG-PET/CT 扫描出现了极高的假阳性率。
Am J Hematol. 2013 May;88(5):400-5. doi: 10.1002/ajh.23423. Epub 2013 Mar 19.
6
Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.利妥昔单抗与低剂量环磷酰胺、阿霉素、长春新碱和泼尼松龙联合治疗老年弥漫性大B细胞淋巴瘤的疗效及耐受性
Hematology. 2019 Dec;24(1):52-59. doi: 10.1080/10245332.2018.1509461. Epub 2018 Aug 11.
7
Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.年龄组对接受 R-CHOP 方案治疗弥漫性大 B 细胞淋巴瘤患者发热性中性粒细胞减少症风险评估和管理的影响。
Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):297-305. doi: 10.1016/j.clml.2012.06.004.
8
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.环磷酰胺、多柔比星、长春新碱、泼尼松和利妥昔单抗与表柔比星、环磷酰胺、长春碱、泼尼松和利妥昔单抗用于初治老年“适合”弥漫性大 B 细胞淋巴瘤患者：意大利淋巴瘤研究组的 ANZINTER3 试验结果。
Leuk Lymphoma. 2012 Apr;53(4):581-8. doi: 10.3109/10428194.2011.621565. Epub 2011 Nov 15.
9
Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.对于老年弥漫性大 B 细胞淋巴瘤患者，采用低剂量 21 天周期利妥昔单抗和环磷酰胺、多柔比星、长春新碱和泼尼松治疗的疗效和耐受性。
Leuk Lymphoma. 2013 Nov;54(11):2441-7. doi: 10.3109/10428194.2013.780654. Epub 2013 Apr 17.
10
A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.老年弥漫性大B细胞淋巴瘤患者的宿主依赖性预后模型
Oncologist. 2017 May;22(5):554-560. doi: 10.1634/theoncologist.2016-0260. Epub 2017 Apr 13.

引用本文的文献

1
Complete Regression of Primary Cardiac Lymphoma With Dose-Attenuated R-CVP Chemotherapeutic Regimen.采用剂量减毒的R-CVP化疗方案使原发性心脏淋巴瘤完全消退
JACC Case Rep. 2019 Sep 4;1(3):332-336. doi: 10.1016/j.jaccas.2019.06.033. eCollection 2019 Oct.
2
Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: a population-based study in Taiwan, 2010-2015.2010 - 2015年台湾地区老年弥漫性大B细胞淋巴瘤患者的一线治疗：一项基于人群的研究
Immun Ageing. 2020 Jun 10;17:17. doi: 10.1186/s12979-020-00188-8. eCollection 2020.
3
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
一项评估抗 CD19 抗体药物偶联物 coltuximab ravtansine（SAR3419）在既往接受基于利妥昔单抗免疫治疗的复发或难治性弥漫性大 B 细胞淋巴瘤患者中的疗效和安全性的多中心 II 期研究。
Haematologica. 2018 Aug;103(8):1351-1358. doi: 10.3324/haematol.2017.168401. Epub 2018 May 10.